EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Late Wilate Prophylaxis Initiation in Adult Twins with Type 3 von Willebrand Disease: Overcoming Historical Barriers and Improving Clinical Outcomes

Cristina Sierra iD, Maria José Ojinaga, Lucia Insunza, Gorka Pinedo, Javier Arzuaga, Juan Carlos García-Ruiz

TH Open · 05.11.2026 · 10 (CP)

DOI: 10.1055/a-2990-4466 ↗

Kurz gefasst

Fallbericht in der Zeitschrift TH Open, online erschienen am 05.11.2026. Verfasst von Cristina Sierra und 5 weiteren Autor:innen. Beteiligte Einrichtung: Haemostasis and Thrombosis UnitCruces University HospitalBizkaiaBasque CountrySpain. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Octapharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prophylaxis with a plasma-derived von Willebrand factor/factor VIII (pdVWF/FVIII) 1:1 concentrate (wilate) is effective in the treatment of severe type 3 von Willebrand disease (VWD). However, uptake of prophylaxis with factor concentrates remains limited due in part to the treatment burden and historical concerns over blood product safety. We describe clinical cases of two adult twin brothers with severe type 3 VWD and a history of hepatitis C acquired from childhood plasma-derived products, who initiated once-weekly pdVWF/FVIII 1:1 concentrate prophylaxis after years of on-demand therapy. Both patients completed 12 months of prophylaxis, which led to a marked improvement in bleeding control and daily functioning, and a decrease in treatment burden compared with on-demand treatment. Their experiences highlight the significant enhancement in quality of life achieved through the adoption of regular prophylaxis. Overcoming long-standing concerns about product safety allowed them to embrace preventive care and realize its benefits in managing their severe VWD.

Schlagwörter

Stichwörter der Autor:innen

Von Willebrand diseaseplasma-derived von Willebrand factorprophylaxis

Autor:innen und Institutionen

  • Haemostasis and Thrombosis UnitCruces University HospitalBizkaiaBasque CountrySpain.
  • Molecular Biology LaboratoryCruces University HospitalBizkaiaBasque CountrySpain.
  • Department of Haematology and HaemotherapyCruces University HospitalBizkaiaBasque CountrySpain.

ORCID-Profile: Cristina Sierra

Förderung

  • Octapharma AG

Zitieren

APA

Sierra, C., Ojinaga, M. J., Insunza, L., Pinedo, G., Arzuaga, J., & García-Ruiz, J. C. (2026). Late Wilate Prophylaxis Initiation in Adult Twins with Type 3 von Willebrand Disease: Overcoming Historical Barriers and Improving Clinical Outcomes. TH Open, 10(CP). https://doi.org/10.1055/a-2990-4466

Vancouver

Sierra C, Ojinaga MJ, Insunza L, Pinedo G, Arzuaga J, García-Ruiz JC. Late Wilate Prophylaxis Initiation in Adult Twins with Type 3 von Willebrand Disease: Overcoming Historical Barriers and Improving Clinical Outcomes. TH Open. 2026;10(CP). doi:10.1055/a-2990-4466

BibTeX
@article{Sierra2026,
  author = {Sierra, Cristina and Ojinaga, Maria José and Insunza, Lucia and Pinedo, Gorka and Arzuaga, Javier and García-Ruiz, Juan Carlos},
  title = {Late Wilate Prophylaxis Initiation in Adult Twins with Type 3 von Willebrand Disease: Overcoming Historical Barriers and Improving Clinical Outcomes},
  journal = {TH Open},
  year = {2026},
  volume = {10},
  number = {CP},
  doi = {10.1055/a-2990-4466}
}
Kostenlos starten →